LiverMultiScan’s cT1 was used alongside other technologies to identify new indications for existing type 2 diabetes drugs. cT1 confirmed an absence of treatment effect of dapagliflozin in this small NAFLD cohort.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?